– BASAGLAR is the first FDA-approved follow-on insulin glargine treatment – BASAGLAR will be available in the U.S. starting on December 15, 2016 INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 16, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) granted […]
– VIBERZI is a First-In-Class, Proactive Treatment Option for Adults Suffering From IBS-D DUBLIN, Dec. 14, 2015 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that VIBERZI™ (eluxadoline), the company’s first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D), is now available by prescription in the U.S. “We are excited […]
Praluent® is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies, including OptumRx and UnitedHealthcare Commercial, Medicare, and Managed Medicaid formularies BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Dec. 11, 2015 /PRNewswire/ — Sanofi and Regeneron Pharmaceuticals, Inc. today announced that UnitedHealth Group will provide preferred access to Praluent® (alirocumab) Injection through OptumRx and UnitedHealthcare for Commercial, […]
Coartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300 million Coartem® Dispersible treatments without profit, mostly to the public sector, to treat children suffering from malaria Together with other innovations, Coartem® Dispersible contributed to reduce the malaria death […]
Regulatory applications for venetoclax have been submitted to the U.S. Food and Drug Administration and European Medicines Agency Additional results in previously treated chronic lymphocytic leukaemia from a separate Phase Ib study published online today in New England Journal of Medicine Basel, 7 December 2015 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new, […]
Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo Three Pivotal Studies Form the Basis for Global Regulatory Filings, Planned In 2015 THOUSAND OAKS, Calif. and LONDON, Nov. 25, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-2TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab […]
THOUSAND OAKS, Calif., Nov. 24, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 and RILOMET-2 studies. Amgen’s decision is based on a planned safety review by the RILOMET-1 independent data monitoring committee that found an increase in the […]
GE Healthcare to offer Caradigm’s Identity and Access Management suite with Omnyx digital pathology solutions to streamline pathology workflows. PITTSBURGH, PA – November 19, 2014 – GE Healthcare, a leader in technology innovation, today announced it will resell Caradigm’s Single Sign-On and Context Management solutions in the United States, Canada, and specific EU countries to […]
Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 WHITEHOUSE STATION, N.J., November 3, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation […]
Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent Amgen to Webcast Investor Call at AHA Scientific Sessions 2014 THOUSAND OAKS, Calif., Nov. 18, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational […]